Kee Song Bio-Technology Holdings Ltd said its normalized net income for the third quarter was NT$1.01 per share, compared with the S&P Capital IQ consensus estimate of NT$1.10 per share.
EPS climbed year over year from 40 cents.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was NT$35.5 million, a gain from NT$13.6 million in the prior-year period.
The normalized profit margin climbed to 6.4% from 4.1% in the year-earlier period.
Total revenue grew 68.7% year over year to NT$558.1 million from NT$330.7 million, and total operating expenses grew 58.2% year over year to NT$493.0 million from NT$311.7 million.
Reported net income rose from the prior-year period to NT$45.2 million, or NT$1.29 per share, from NT$16.0 million, or 47 cents per share.
As of Nov. 16, US$1 was equivalent to NT$32.83.